Identifican nuevas pistas del Alzheimer

Una proteína del plasma parece relacionarse con el desarrollo y avance de la enfermedad, según un estudio
MARTES, 6 de julio (HealthDay News/HolaDoctor) -- Las altas concentraciones de una proteína del plasma sanguíneo llamada clusterina podrían influenciar el desarrollo, gravedad y avance de la enfermedad de Alzheimer, informan investigadores ingleses.

Llevaron a cabo evaluaciones clínicas y escáneres de imágenes cerebrales, y analizaron muestras de plasma sanguíneo de personas que sufrían de enfermedad de Alzheimer, deterioro cognitivo leve (un precursor del Alzheimer) o que no tenían demencia.

El equipo del Instituto de Psiquiatría del Colegio del Rey de Londres encontró una asociación entre los niveles de clusterina en el plasma sanguíneo y la gravedad de la enfermedad de Alzheimer, su avance rápido, y atrofia en un área del cerebro llamada corteza entorrinal, que tiene que ver con la memoria.

Los investigadores también concluyeron que los niveles altos de clusterina en el plasma sanguíneo se relacionaban con un aumento en la beta amiloidea (una proteína que forma las placas cerebrales asociadas con el Alzheimer) en el lóbulo temporal medio del cerebro.

El estudio aparece en la edición de junio de la revista Archives of General Psychiatry.

Estudios anteriores habían sugerido que las clusterinas pertenecen a una familia de proteínas llamadas chaperonas extracelulares, que regulan la formación y eliminación de la amiloidea, apuntaron los investigadores.

"Aunque estos hallazgos no respaldan la utilidad clínica de la concentración de clusterina en plasma como biomarcador independiente de la enfermedad de Alzheimer, revelan una robusta firma periférica de esta proteína chaperona de la amiloidea que responde a las características claves de la patología de la enfermedad", escribieron en un comunicado de prensa del editor.

"Nuestros hallazgos implican claramente a la clusterina, y muy bien podrían haber otras proteínas en plasma relacionadas con el proceso de la enfermedad. De hecho, nuestros estudios previos y los de otros investigadores sugieren que es así", concluyeron. "Estos resultados podrían tener implicaciones más amplias para la identificación de otras proteínas chaperonas de la amilodea en el plasma, tanto como potenciales biomarcadores de la enfermedad de Alzheimer y como objetivos

http://www.nlm.nih.gov/medlineplus/spanish/news/fullstory_100759.html
Artículo por HealthDay, traducido por Hispanicare

FUENTE: JAMA/Archives journals, news release, July 5, 2010

HealthDay

Comments

Nordic Walking Benefits, ADHD and Diet, Supplements and Cancer, Sources of Fiber

A Better Way To Walk: Nordic Walking Improves Quality of Life, Depression, and Functional Capacity SciTechDaily Reference: “Sustained Effects of Different Exercise Modalities on Physical and Mental Health in Patients With Coronary Artery Disease: A Randomized ... Dietary Interventions for ADHD: Emerging Research and Considerations There has been increasing interest in the role that diet and supplements play in the treatment of attention-deficit/hyperactivity disorder (ADHD) symptoms, from patients and researchers alike. Diet is an important treatment approach to consider, as it is a lifestyle change rather than a medication. Additionally, at least 10% to 30% of children with ADHD are non-responsive to, or experience adverse effects from, ADHD medications.1 A dietary approach to ADHD can be complementary to a conventional pharmacological approach, giving patients and their families more options toward a personalized treatment plan. This article will examine current research about di

More People Are Microdosing for Mental Health. But Does It Work?

By Dana G Smith. Joseph started microdosing psychedelics five years ago to try to improve his mental health. “I was just kind of in this depression, in this rut,” he said. “I was unhappy and angry and agitated all the time, and it went against the way that I saw myself.” Depression and anxiety run in Joseph’s family, and he’d been prescribed Prozac as a kid. But when symptoms of depression returned in his early 30s, he didn’t want to go back to a prescription drug. Joseph, an Austin-based designer (he asked to withhold his full name, citing privacy concerns surrounding mental health issues and illegal drug use), came across research from Johns Hopkins University about psilocybin, the active ingredient in hallucinogenic, or “magic,” mushrooms. In a small study, full doses of the drug helped cancer patients cope with depression and anxiety. Then he read anecdotes of Silicon Valley influencers claiming increased energy from taking tiny doses of psychedelics. So he decided to start microdo

Exploring the Link Between Circadian Rhythms, Longevity, and Wearable Data: Insights and Future Directions

A recent study in NHANES 2011–2014 explores the potential connection between disruptions in circadian rhythms, measured using wearable devices, and their impact on health outcomes and longevity. The study analyzes data from 7,297 U.S. adults collected through wearable accelerometers as a novel digital biomarker for longevity. Five distinct clusters were identified based on activity profiles: "High activity," "Low activity," "Mild circadian rhythm (CR) disruption," "Severe CR disruption," and "Very low activity." The findings reveal that young adults with extreme circadian rhythm disturbance exhibit higher white blood cell counts and accelerated biological aging. Older adults with circadian disruption are associated with increased systemic inflammation indexes, advanced biological aging, and higher all-cause mortality risk. The research underscores the importance of circadian alignment for longevity at all ages and suggests that wearable

Wellness-uptodate

Search This Blog